Efficacy of open‐label counterconditioning for reducing nocebo effects on pressure pain
Open Access
- 3 April 2023
- journal article
- research article
- Published by Wiley in European journal of pain
- Vol. 27 (7) , 831-847
Abstract
BackgroundNocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning. However, open-label counterconditioning, in which participants are informed about the placebo content of the treatment, has not been investigated, while this can be highly relevant for clinical practice. Furthermore, (open-label) conditioning and counterconditioning has not been investigated for pain modalities relevant to musculoskeletal disorders, such as pressure pain. MethodsIn a randomized controlled trial, we investigated in 110 healthy female participants whether nocebo effects on pressure pain combined with open-label verbal suggestions can be (1) induced via conditioning and (2) reduced via counterconditioning. Participants were allocated to either a nocebo- or sham-conditioning group. Next, the nocebo group was allocated to either counterconditioning, extinction or continued nocebo conditioning; sham conditioning was followed by placebo conditioning. ResultsNocebo effects were significantly larger after nocebo conditioning than sham conditioning (d = 1.27). Subsequently, a larger reduction of the nocebo effect was found after counterconditioning than after extinction (d = 1.02) and continued nocebo conditioning (d = 1.66), with effects similar to placebo conditioning (following sham conditioning). ConclusionsThese results show that (counter)conditioning combined with open-label suggestions can modulate nocebo effects on pressure pain, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders, particularly for musculoskeletal disorders. SignificanceFew studies have investigated the efficacy counterconditioning to reduce nocebo effects. Whereas typically deceptive procedures are used, these are not ethically appropriate for use in clinical practice. The current study demonstrates that open-label counterconditioning in a pain modality relevant for many chronic pain conditions may be a promising new strategy for reducing nocebo effects in a non-deceptive and ethical manner, which provides promise in designing learning-based treatments to reduce nocebo effects in patients with chronic pain disorders.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- The acquisition of fear of movement-related pain and associative learning: A novel pain-relevant human fear conditioning paradigmPain, 2011
- Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel SyndromePLOS ONE, 2010
- How the number of learning trials affects placebo and nocebo responsesPain, 2010
- Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked painPain, 2009
- The role of learning in nocebo and placebo effectsPain, 2008
- When words are painful: Unraveling the mechanisms of the nocebo effectNeuroscience, 2007
- Deception in Research on the Placebo EffectPLOS Medicine, 2005
- Cortical correlates of false expectations during pain intensity judgments—a possible manifestation of placebo/nocebo cognitions☆Brain, Behavior, and Immunity, 2005
- Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanismsPain, 2005
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990